Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.575 AUD | +6.48% | +16.16% | +180.49% |
May. 29 | Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy | MT |
May. 27 | Dimerix Signs License Deal for Kidney Disease Medication in the Middle East | MT |
Sales 2022 | 6.47M 4.27M | Sales 2023 | 8.98M 5.94M | Capitalization | 24.06M 15.9M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.61M | Net income 2023 | -13M -8.59M | EV / Sales 2022 | 4.48 x |
Net cash position 2022 | 9.56M 6.31M | Net cash position 2023 | 2.03M 1.34M | EV / Sales 2023 | 2.45 x |
P/E ratio 2022 |
-3.37
x | P/E ratio 2023 |
-1.46
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95.78% |
1 day | +6.48% | ||
1 week | +16.16% | ||
Current month | +16.16% | ||
1 month | +71.64% | ||
3 months | +91.67% | ||
6 months | +325.93% | ||
Current year | +180.49% |
Managers | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hamish George
DFI | Director of Finance/CFO | - | 19-05-05 |
David Fuller
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hugh Alsop
BRD | Director/Board Member | - | 17-04-30 |
Mark Diamond
CHM | Chairman | - | 23-01-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.575 | +6.48% | 4,754,945 |
24-06-06 | 0.54 | +10.20% | 6,829,790 |
24-06-05 | 0.49 | -1.01% | 5,015,974 |
24-06-04 | 0.495 | -1.98% | 10,710,030 |
24-06-03 | 0.505 | +2.02% | 5,293,929 |
Delayed Quote Australian S.E., June 07, 2024 at 02:11 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+180.49% | 208M | |
+48.67% | 57.87B | |
+41.65% | 40.25B | |
-6.96% | 39.94B | |
-5.96% | 28.54B | |
+12.69% | 26.4B | |
-20.08% | 19.33B | |
+30.79% | 12.4B | |
-0.22% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- DXB Stock